The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus.

Simo Liu Jing Ke Xiaotong Feng Zongwei Wang Xin Wang Long-Yan Yang Dong Zhao

Published in: Journal of diabetes research (2024)

Canagliflozin increases HDL-c level and suppresses ANGPTL3 expression in patients with T2DM and diabetic mice. The reduction of ANGPTL3 may contribute to the increase of HDL-c. However, the specific mechanism needs further research. This trial is registered with ChiCTR1900021231.

Keyphrases

poor prognosis
phase iii
study protocol
signaling pathway
clinical trial
phase ii
binding protein
glycemic control
open label
metabolic syndrome